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ScienceDirectConnective tissue calcifying diseases (CTCs) are characterized
by abnormal calcium deposition in connective tissues. CTCs
are caused by multiple factors including chronic diseases (Type
II diabetes mellitus, chronic kidney disease), the use of
pharmaceuticals (e.g. warfarin, glucocorticoids) and inherited
rare genetic diseases such as pseudoxanthoma elasticum
(PXE), generalized arterial calcification in infancy (GACI) and
Keutel syndrome (KTLS). This review explores our current
knowledge of these rare inherited CTCs, and highlights the
most promising avenues for pharmaceutical intervention.
Advancing our understanding of rare inherited forms of CTC is
not only essential for the development of therapeutic strategies
for patients suffering from these diseases, but also fundamental
to delineating the mechanisms underpinning acquired chronic
forms of CTC.
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Introduction
A disease or disorder is defined as rare in Europe when it
affects less than 1 in 2000 people. In the EU, as many as
30 million people alone may be affected by one of over
6000 existing rare diseases (http://www.eurordis.org/
about-rare-diseases). A number of rare inherited forms ofCurrent Opinion in Pharmacology 2016, 28:14–23 Connective Tissue Calcifying diseases (CTCs) have been
identified, and are characterized by abnormal calcium
mineral deposition in connective tissues. Although all
tissue has the potential to undergo calcification, several
tissues have a higher propensity to calcify including skin,
kidney, blood vessels and cardiac valves [1]. There are
multiple mechanisms by which connective tissue calcifica-
tion can progress, however these mechanisms are not
exclusive and multiple pathologies can concurrently pro-
mote aberrant calcification. Common causes of connective
tissue calcification include aging, as well as diseases such as
atherosclerosis, chronic kidney disease (CKD) and Type II
diabetes mellitus. Connective tissue calcification is also the
result of specific rare congenital diseases such as general-
ized arterial calcification of infancy (GACI), pseudox-
anthoma elasticum (PXE), Hutchinson–Gilford progeria
syndrome (HGPS), arterial calcification due to deficiency
of CD73 (ACDC) and Keutel syndrome (KTLS) [2].
Despite scarcity of cases, these diseases provide significant
insight into the complex biological processes underpinning
connective tissue calcification. The single gene deficien-
cies of rare inherited forms of CTC have allowed the
identification of specific targets and the development of
novel animal models to further study the process of con-
nective tissue calcification. Furthermore, data from
patients and animal models has resulted in the elucidation
of pathways involved in both the promotion and inhibition
of connective tissue calcification.
Basic mechanisms of bone mineralization
In order to understand more fully the mechanisms under-
pinning connective tissue calcification, it is important to
appreciate the physiological process of bone mineraliza-
tion, which occurs through the deposition of hydroxyapa-
tite (HA) onto a collagenous extracellular matrix (ECM).
HA crystal formation is regulated by matrix vesicles (MVs),
which maintain calcium (Ca2+) and inorganic phosphate
(Pi) concentrations at levels optimal for HA nucleation. As
the HA crystals grow they disrupt the MV and deposit onto
the ECM where they continue to grow [3]. The transport of
Ca2+ into MVs is primarily controlled by annexin channels,
whereas Pi is transported into the MV by the type III
sodium-dependent Pi co-transporter-1 (PiT-1) [4]. Intra-
cellular to extracellular channelling of pyrophosphate (PPi)
is mediated by ANK [5].
Whilst Pi acts to promote HA crystal formation, PPi,
generated by ecto-nucleotide pyrophosphatase/phospho-
diesterase 1 (ENPP1), has a dual role as an inhibitor of HAwww.sciencedirect.com
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PPi is controlled by a complex interaction between the
regulatory phosphatases tissue non-specific alkaline phos-
phatase (TNAP) and phosphoethanolamine/phosphocho-
line phosphatase (PHOSPHO1). TNAP hydrolyses PPi in
the ECM to release Pi and PHOSPHO1 hydrolyses
phosphocholine and phosphoethanolamine to produce
Pi inside the MVs. Together these phosphatases control
the Pi/PPi balance during the mineralization process [7].
Further feedback signalling allows modulation of miner-
alization; inorganic pyrophosphatase stimulates minerali-
zation without reducing PPi levels [8]. Both exogenous Pi
and PPi upregulate the bone sialoprotein osteopontin
(OPN), which in turn inhibits mineralization through
restricting HA crystal formation and growth [9]. Intrigu-
ingly, a clear dissociation in the hierarchical roles of PPi
and OPN has recently been highlighted [10].
Overview of mechanisms of connective tissue
calcification
The control and regulation of connective tissue calcifica-
tion is a multifactorial process which shares many similari-
ties with that of the physiological matrix mineralization
during skeletal development described previously. A
wealth of knowledge emanates from research into vascular
calcification, a strong and independent predictor of mor-
bidity and mortality in cardiovascular disease [2]. Indeed
normal vascular smooth muscle cell (VSMC) populations
contain cells that undergo phenotypic transition to osteo-
cytic, osteoblastic and chondrocytic cells in a calcified
environment [11]. In VSMCs, MVs have been shown to
nucleate hydroxyapatite crystals that contain calcium and
inorganic phosphate [12] forming the first nidus for
calcification. This nucleation occurs via a tightly controlledTable 1
The cause and phenotype of significant rare inherited CTCs
CTC disease 
Pseudoxanthoma elasticum (PXE) ABCC6 deficie
Generalized arterial calcification in infancy (GACI) ENPP1 deficie
Arterial calcification due to deficiency of CD73 (ACDC) CD73 deficienc
Hutchinson–Gilford progeria syndrome (HGPS) Progerin (lamin
Keutel syndrome (KTLS) MGP deficienc
Fibrodysplasia ossificans progressiva (FOP) ACVR1 gain of
Coeliac disease with epilepsy and cerebral
calcifications (CEC)
Unknown 
Idiopathic basal ganglia calcification (IBGC) PiT-2 and/or P
www.sciencedirect.com balance of inhibitors and inducers comparable to that seen
in bone, with PHOSPHO1, sphingomyelinase 3 (SMPD3),
TNAP, annexins, ANK and ENPP1 playing key regulatory
roles [2,12]. Furthermore, MVs derived from VSMCs
have been shown to contain negative regulators of hydroxy-
apatite crystal nucleation and growth, such as fetuin-A and
matrix gla protein (MGP) [13]. In cooperation with local
mediators such as PPi [6], these molecules protect the
arteries from mineral deposition and growth. In the ab-
sence of these inhibitors, or following the stimulation of
apoptotic processes [14], together with the osteogenic
activity of VSMCs, vascular calcification readily proceeds.
A key role for pyrophosphate (PPi) in rare
CTCs
It has recently been established that connective tissue
calcification is contingent on circulating PPi levels rather
than local PPi production [15]. As previously highlighted,
PPi not only acts as a potent inhibitor of connective tissue
calcification, but also contributes directly to the calcifica-
tion process. Intriguingly, one of the identified sources of
systemic PPi is through ATP binding cassette sub-family
C member 6 (ABCC6)-mediated ATP release from hepa-
tocytes [16]. Still within the vasculature of the liver,
released ATP is rapidly converted to PPi and AMP by
ENPP1, which are in turn distributed throughout the
body via the circulation. In connective tissues the metab-
olite AMP is further hydrolysed into Pi and adenosine by
ecto-50-nucleotidase (CD73). Adenosine in turn inhibits
TNAP transcription, thus decreasing Pi production and
more importantly maintaining PPi levels [17]. Different
perturbations in this mechanism can contribute to several
rare CTCs (Table 1) which whilst varying in degree of
severity and phenotype, show notable overlap.Cause Phenotype
ncy Elastic fibre mineralization in skin, eyes, and
arteries.
ncy Widespread mineralization of arteries, and to
a lesser extent joints.
y Mineralization of arteries and joints in the
extremities.
 A mutant) Premature aging, atherosclerosis and
calcification of blood vessels and the aortic
valve.
y Facial abnormalities, calcification of the
larynx trachea and bronchi, along with
auricular, nasal and rib cartilage.
 function Progressive heterotopic endochondral
ossification of skeletal muscle, fascia,
tendons, and ligaments.
Occipital epilepsy, with bilateral occipital
calcifications and coeliac disease.
DGFR-B deficiency? Calcification of the basal ganglia as well as
the thalamus and cerebellum.
Current Opinion in Pharmacology 2016, 28:14–23
16 MusculoskeletalDisease models of connective tissue
calcification
Pseudoxanthoma elasticum (PXE)
A defect in the ABCC6 gene is responsible for pseudox-
anthoma elasticum (PXE) (#OMIM 264800), an inherited
autosomal recessive multisystem disorder affecting con-
nective tissues in humans. The ABCC6 gene carried by
chromosome 16p13.11 encodes a trans-membrane ATP-
binding cassette transporter, subfamily C, member 6 [15],
which is primarily expressed in the hepatocyte and to a
lesser extent in the proximal tubule cells in the kidney.
The phenotypic expression of the disease is characterized
by the fragmentation and mineralization of elastic fibres
in the skin, retina and arterial wall [16–18]. The symp-
toms are represented by unaesthetic skin folds, central
blindness and adverse cardiovascular events (Figure 1).
To date, the role of ABCC6 and the nature of its sub-
strate(s) in the PXE disease remain unknown and are
presently subject to extensive research efforts worldwide.
After several inconclusive hypotheses, recent seminal
studies disclosed that ABCC6 participates in the release
of intracellular nucleotides (such as ATP) by a yet un-
known pathway in the liver [19]. This results in a
decrease in the extracellular ATP available for degrada-
tion by hepatic ecto-nucleotidase enzymes (such as
ENPP1), which ultimately leads to less circulating PPi,
a powerful tissue and circulating anti-calcifying factor (as
highlighted above) [20]. This important study places the
liver, and to a lesser extent the kidney, as the metabolicFigure 1
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Diffuse arterial calcifications visualized by CT-scan in the lower limb
arteries of a patient with pseudoxanthoma elasticum (PXE).
Current Opinion in Pharmacology 2016, 28:14–23 control centre of PXE associated calcification, with almost
40% of the overall systemic PPi production generated
from the liver [21], which cannot be compensated for by
the local release of PPi through alternative ectonucleoti-
dic pathways (i.e. ENPP1 or TNAP).
Additional confounding factors of genetic [22] and/or met-
abolic origin [23–25] highlight the complex direct and
remote interactions in PXE. Further clinical manifesta-
tions of PXE, such as elevated thrombotic susceptibility,
increased myogenic tone and vascular malformations
[26,27] may be a result of altered purinergic signalling,
which unequivocally mediates complex autocrine and
paracrine cellular signalling pathways within various
tissues [28–31].
PXE represents a prototypic metabolic disease that shares
some of the features of calcifying vascular diseases of
acquired metabolic origin such as type II diabetes melli-
tus and CKD [2]. The discovery of the role of ABCC6
raises new challenging questions on the central role of the
hepato-renal axis in the connective-tissue calcifying pro-
cess. From a clinical point of view, the current absence of
an efficient targeted therapy requires the tight control and
management of the typical cardiovascular risk factors
associated with PXE, in addition to the limitation of
pro-calcifying conditions. Promising new perspectives
for etiologic treatments are however in progress, and
may shortly yield exciting new treatment options for
patients with PXE.
Generalized arterial calcification in infancy (GACI)
Mutations in ENPP1 are known to cause a rare human
disease phenotype, namely generalized arterial calcifica-
tion in infancy (GACI, MIM# 208000), formerly known as
idiopathic infantile arterial calcification (IIAC) [32]. In
GACI, calcification of the media of large and medium-
sized arteries (Figure 2a) is associated with intimal pro-
liferation (Figure 2b) leading to arterial stenosis. Depend-
ing on the severity and the local distribution of the calcific
stenoses, affected infants can present with neonatal heart
failure, arterial hypertension and death within the first six
months of life [33]. To date, more than 40 different
causative mutations in ENPP1 have been identified in
GACI patients accounting for approximately 70% of the
affected cases [33]. Based on the number of reported
pathogenic variants in NHLBI ESP6500 (16 carriers in
6021 individuals) a carrier frequency of one in 376 indi-
viduals (0.27%), and a disease frequency of one in 566,000
individuals can be estimated [34].
The cardiovascular phenotype of the disease is quite
variable [35] and can even vary to a great extent between
siblings carrying the same mutations: of two Taiwanese
siblings with identical genotype, one developed exten-
sive arterial calcification and severe hypertension, and
died of heart failure at the age of 6 weeks, while the otherwww.sciencedirect.com
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Figure 2
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(a) (b)
(a) Sonography of the femoral artery (Fem Art, arrows) of an infant with Generalized Arterial Calcification of Infancy (GACI). Note the increased
echogenicity of the arterial wall. (b) Histology section of the aorta from an infant who died from GACI. Note the deposition of crystallized material
(arrows) at the level of the lamina elastica interna and myointimal proliferation (H&E staining).sibling had an uncomplicated clinical course [36]. The
phenotype of the disease is recapitulated in the so-called
tiptoe-walking (ttw/ttw) mouse associated with articular
cartilage and peri-spinal ligament calcification and also
with aortic calcification [37,38]. In these mice, connective
tissue calcification progresses to hyperostotic joints and
spine ankylosis leading to the ‘tiptoe-walking’ pheno-
type. A comparable phenotype can be found in asj/asj
mice, which carry the V246D missense mutation [39,40]
and in Enpp1 knockout mice [41,42,43]. Intriguingly,
deficiency of ENPP1 has also been shown to exert pro-
tective effects against obesity and diabetes in mice [44],
however, the metabolic phenotype has yet to be assessed
in GACI patients, and warrants future investigation.
Hypophosphataemia can compensate for the GACI phe-
notype and this might reflect a physiologic compensation
mechanism rather than a primary defect [33]. However,
several mutations in the ENPP1 gene can result in the
phenotype of autosomal-recessive hypophosphatemic
rickets (ARHR) without any arterial calcification
[45,46], suggesting a different pathway involved in the
generation of ARHR linked to direct renal Pi-handling
functions of ENPP1. Treatment with synthetic analogues
of pyrophosphate, namely bisphosphonates seems to sig-
nificantly increase survival in patients with GACI [33],
however, spontaneous regression of the calcifications can
occur [47], and studies on the exact long term natural
history of the disease are pending. Based on the finding
that mutations in ENPP1 can also cause PXE and that
mutations in ABCC6 can also cause GACI it has become
obvious that an overlap of genotype and phenotype inwww.sciencedirect.com GACI and PXE exists [48]. This has led to the hypothesis
of a shared pathogenic principle in GACI and PXE [49],
which finally held to be true. Most recently, subcutaneous
administration of an ENPP1-Fc fusion protein was shown
to prevent the mortality, vascular calcifications and se-
quelae of disease in the asj/asj mouse model of GACI
[50]. This very promising preclinical study may pave
the way to clinical trials with enzyme replacement thera-
py in patients with this rare disorder carrying mutations in
ENPP1.
Arterial calcification due to deficiency of CD73 (ACDC)
Calcification of joints and arteries (arterial calcification
due to deficiency of CD73 (ACDC); OMIM# 211800), as
originally described by Magnus-Levy [51] was recently
shown to be caused by deficiency of CD73, encoded by
the NT5E gene [52,53]. Clinical features include calci-
fied large vessels and periarticular calcifications in the
joints of the hands and feet. CD73 has 50 exonucleotidase
activity that converts AMP to adenosine and Pi [54].
Receptor binding of adenosine triggers a downstream
intracellular signalling cascade that results in inhibition
of TNAP activity [55]. Thus, it has been proposed that
increased TNAP activity is central to the mechanism
underpinning ACDC.
Hutchinson–Gilford progeria syndrome
The rare premature aging disorder Hutchinson–Gilford
progeria syndrome (HGPS) is characterized by excessive
atherosclerosis and both blood vessel and aortic valve
calcification [56–58]. HGPS patients express progerin, a
mutant form of lamin A. Progerin expression results inCurrent Opinion in Pharmacology 2016, 28:14–23
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mal higher-order chromatin organization [59,60]. Knock-
in mice expressing progerin exhibit reduced circulating
PPi levels similar to mice lacking ENPP1 [61]. Interest-
ingly this low PPi is the result of increased TNAP activity
and decreased extracellular ATP due to mitochondrial
dysfunction. Consistent with this observation of
supressed PPi levels, these mice show excessive aortic
calcification which is ameliorated by exogenous PPi ad-
ministration [61]. These findings suggest connective tis-
sue calcification in HGPS shares key features of PXE
(decreased ATP), GACI (low PPi) and ACDC (increased
TNAP activity), further demonstrating the overlap be-
tween these CTCs.
Keutel syndrome
Keutel syndrome (KTLS) (OM#245150) is an extremely
rare autosomal recessive disorder that manifests during
the early childhood of patients predominantly from the
Middle East. Since its first description in 1971 by Keutel
and colleagues in two consanguineous siblings [62], less
than 30 patients have been reported to date.
Foremost clinical characteristics of KTLS include abnor-
mal calcification in laryngal, tracheobronchial, auricular,
nasal and rib cartilage, brachytelephalangism and facial
abnormalities such as mid-facial hypoplasia, depressed
nasal bridge and reduced alae nasi [62–67]. Further
symptoms include mild to severe unilateral or bilateral
hearing loss, multiple peripheral pulmonary artery steno-
sis, mental retardation and respiratory conditions, includ-
ing dyspnoea and cough, that lead to hospitalization and
incidentally to diagnosis [62–68]. Additionally, long-term
follow-up studies have revealed that, KTLS patients
develop skin lesions, typically after 30 years of age [69]
and suffer chronic and progressive respiratory disease
caused by gradual laryngotrachebronchial calcification
and stenosis [65,69]. Subsequent post-mortem examina-
tion of the youngest sibling originally described has also
uncovered calcification of pulmonary, coronary, hepatic,
renal, meningeal and cerebral arteries [65–68].
It is well established that KTLS is due to loss-of-function
mutations in the MGP gene [66,67,70–72], encoding
MGP, a potent local mineralization inhibitor predomi-
nantly expressed by chondrocytes and VSMCs [73]. Post-
translational modifications of MGP, such as vitamin K-
dependent glutamate carboxylation and serine phosphor-
ylation, have been shown to trigger these inhibitory
properties [74]. Mice lacking Mgp develop abnormal
cartilage calcification and extensive vascular calcification
that leads to premature death due to aortic dissection [73].
Although all of the seven mutations reported in humans
predict absent or non-functional MGP, they result in
variable phenotypes with cardinal and secondary features
of variable penetrance [66,67,70–72]. Moreover, in con-
trast to Mgp-deficient mice, with the exception of oneCurrent Opinion in Pharmacology 2016, 28:14–23 clinical case [65,67], vascular calcification has not been
observed in KTLS patients. Interestingly, measurements
of circulating MGP species have highlighted high levels
of phosphorylated MGP [67]. This suggests that phos-
phorylation-dependent residual MGP activity may con-
tribute to the absence of arterial calcification and more
generally, that the variable phenotypic features observed
clinically in KTLS could be explained by altered levels of
the different MGP species.
Systemic hypertension is frequently found in KTLS
patients before adulthood. Therefore, under the control
of standard anti-hypertensive medication [69], KTLS has
a good prognosis. Nevertheless, life expectancy of
patients primarily depends on the severity of the associ-
ated respiratory complications. Indeed, symptomatic
treatment with corticosteroids or bronchodilators is not
always effective [65,67,69]. Interestingly, a recent study
reported the efficacy of BMP inhibitors in reducing
vascular calcification and improving survival in Mgp/
mice [75]. Besides targeting vascular calcification,
which is very rare in KTLS, BMP inhibition strategies
could also be employed as a pharmaceutical approach to
reduce abnormal cartilage calcification. This would have
particularly high therapeutic value if successfully devel-
oped to treat tracheobronchial tree calcification, which
initiates respiratory distress and complications, and ulti-
mately determines the quality and duration of life of
KTLS patients.
Fibrodysplasia ossificans progressiva (FOP)
Fibrodysplasia ossificans progressiva (FOP; OMIM#
135100) is a devastating rare disease, characterized by
the progressive heterotopic endochondral ossification
(HOE) of skeletal muscle, fascia, tendons, and ligaments
[76]. The range of joint motion in FOP patients becomes
gradually and progressively limited by HOE. Indeed,
this ossification is so diffuse that it is commonly referred
to as a second skeleton [76]. HOE occurs in flare ups and
is most commonly triggered by muscle injury, as also
observed in Abcc6/ mice [77], and viral infection. Un-
like other CTCs discussed in this review, FOP is not the
result of a deficiency but rather a gain of function muta-
tion. All patients with the typical FOP phenotype have a
substitution of the Arg206 residue for a His residue in
Activin A receptor type I (ACVR1) which is a type 1 Bone
Morphogenetic Protein Receptor (BMPR) [78]. This
A206H ACVR1 exhibits ligand free activation of its
BMP signalling pathways and a greatly enhanced re-
sponse to BMP [79,80]. Studies suggest that FKBP1A
(a protein that negatively regulates BMP type I R) has
reduced binding capabilities to A206H ACVR1, prevent-
ing it from modulating its activity [79–81]. Knock-in mice
that express the A206H ACVR1 recapitulate the pheno-
type of FOP patients [82], with data from these mice and
other models suggesting that Tie2+ mesenchymal cells
are the progenitors of the HOE through their response towww.sciencedirect.com
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FOP symptoms is limited to glucocorticoids and non-
steroidal anti-inflammatories to minimize flare ups and
pain [76], with no therapeutic strategy currently available
to inhibit or prevent the HOE associated with this rare
CTC. Given the positive effects of BMP inhibitors in
Mgp-deficient mice, it would be beneficial to recapitulate
these studies in the FOP mouse model as a first step to a
pharmaceutical approach.
Rare CTCs of the brain
There are a number of disorders demonstrating con-
nective tissue calcification in the brain, including coe-
liac disease with Epilepsy and Cerebral calcifications
(CEC; OMIM# 226810). To date, less than 200 CECFigure 3
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www.sciencedirect.com patients have been reported in the literature [86]. The
suspected Mendelian basis of this disease is character-
ized by three primary pathologies. The first is epilepsy,
most commonly occipital epilepsy. Drug resistance is
also common for this epilepsy with evolution towards
epileptic encephalopathy. The second pathology is
cerebral calcification, with bilateral occipital calcifica-
tions most frequently observed. The third pathology is
coeliac disease, although in older patients (>2 years)
bowel symptoms are less common [87,88]. Whilst folate
deficiency has been proposed as the cause of CEC [89],
recent studies suggest a possible autoimmune compo-
nent to the disease with the identification of autoanti-
bodies to transglutaminase isoenzyme 6 in the serum of
a CEC patient [90]. Current CEC treatment regimensmitochondrial
dysfunction
TNAP
denosine
OPN
BMPs
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(KTLS )
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(FOP )
ydroxyapatite
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Current Opinion in Pharmacology 2016, 28:14–23
20 Musculoskeletalinclude folate supplementation and gluten free diet,
the efficacy of which has been shown to directly
correlate with how early treatment is implemented
[87,88].
Idiopathic Basal Ganglia Calcification (IBGC; OMIM#
213600) is characterized by calcification of the basal
ganglia as well as the thalamus and cerebellum [91].
Patients display a range of neuropsychiatric and move-
ment disorders including dementia, psychosis, Parkinson-
ism, dystonia, and migraine. Mutations in the gene for
type III sodium-dependent Pi co-transporter 2 (PiT-2)
leading to impaired or loss of function have been identi-
fied in several patient cohorts [92–96]. Direct evidence for
a role for PiT-2 in IBGC was first provided by studies
investigating the phenotype of mice lacking PiT-2.
These mice develop calcification predominantly in the
thalamus but also in the basal ganglia and brain cortex
[97]. Of particular interest, histological analyses of these
mice suggest that calcification initiates in or around the
vasculature which closely mimics the phenotype ob-
served in IBGC patients [91]. Mutations in the gene
for platelet derived growth factor receptor B (PDGFRB)
have also been described in IBGC patients [98].
PDFGRB regulates PiT-1 in VSMCs [99,100] and a role
for this molecule in IBGC would be consistent with a
vascular origin of the calcification. Considering IBGC
patients have normal circulating Pi levels [91] any role
Pit-2 and/or PDGFRB may play in calcification would be
local to the affected tissue. This highlights the heteroge-
neity of Pi regulation in different tissues which should be
an important consideration when planning pharmaceuti-
cal interventions for CTCs.
Future directions
Much of our understanding of the potential mechanisms
underpinning CTCs (Figure 3) has arisen through the use
of rodent models. However, significant differences be-
tween physiology, anatomy, and pathology exist between
mice and men. In contrast, large animal models can show
markedly greater similarity to humans [101]. The recent
explosion of precise and efficient genome editing tech-
niques through CRISPR/Cas9 technology permits the
generation of tailored models for translational research
[102]. These novel systems provide huge potential for
large animal models for future investigations into the
regulatory factors and molecular pathways that contribute
to rare inherited forms of CTC in vivo.
At present, only very limited pharmaceutical strategies
exist to inhibit connective tissue calcification. Further
pre-clinical and clinical studies are required to examine
new approaches such as targeting mechanisms common to
different CTCs (e.g. PPi regulation) and/or enzyme re-
placement therapy (e.g. ENPP1). These investigations
may bring to fruition the first comprehensive treatment
for both inherited and acquired CTCs.Current Opinion in Pharmacology 2016, 28:14–23 Conflict of interest statement
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